E4/DRSP oral contraceptive update ● NDA submission targeted for 1HCY20 with potential approval 1HCY21 ● Finalising selection of brand name and logo, subject to FDA approval ● Multiple advisory boards and conferences across CY20 (eg. APGO/CREOG, ISGE, ESC) to educate healthcare professionals ● Medical Science Liaison team in place to educate pre-launch ● Commercial launch to occur immediately upon approval – planning well advanced ● Launch to be supported by new women’s health sales force ● Participates in US$4b short-acting combined hormonal contraceptive market ● Peak net sales potential to exceed US$200m per annum
MYX Price at posting:
46.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)